Changes in serum levels of heat shock protein 70 in preterm delivery and pre-eclampsia

Aim: The aim of this study was to investigate heat‐shock protein (Hsp)70 as a novel marker to evaluate the curative effects of treatment for preterm delivery high‐risk patients and pre‐eclampsia. Methods: After obtaining informed consent, serum samples were collected from 31 preterm delivery high‐ri...

Full description

Saved in:

Bibliographic Details
Published in:	The journal of obstetrics and gynaecology research Vol. 31; no. 1; pp. 72 - 77
Main Authors:	Fukushima, Akimune, Kawahara, Hisao, Isurugi, Chizuko, Syoji, Tadahiro, Oyama, Rie, Sugiyama, Toru, Horiuchi, Saburo
Format:	Journal Article
Language:	English
Published:	Melbourne, Australia Blackwell Science Pty 01-02-2005
Subjects:	Adult Biomarkers - blood Case-Control Studies Female Gestational Age heat shock protein 70 HSP70 Heat-Shock Proteins - blood Humans Obstetric Labor, Premature - blood Parity pre-eclampsia Pre-Eclampsia - blood Predictive Value of Tests Pregnancy Pregnancy Trimesters - blood preterm delivery
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Aim: The aim of this study was to investigate heat‐shock protein (Hsp)70 as a novel marker to evaluate the curative effects of treatment for preterm delivery high‐risk patients and pre‐eclampsia. Methods: After obtaining informed consent, serum samples were collected from 31 preterm delivery high‐risk patients with a tocolysis index of three points or above (A), seven pre‐eclampsia patients (P), 46 normal pregnant women (B), and seven non‐pregnant women (C). Of the 31 preterm delivery high‐risk patients, 15 had preterm delivery (Ap) and 16 had full‐term delivery (Af ). The levels of Hsp70 were measured using enzyme‐linked immunosorbent assay. Results: The Hsp70 levels in normal pregnant women were 8.6 ± 1.9 ng/mL (first trimester), 5.5 ± 1.0 ng/mL (second trimester) and 5.5 ± 0.7 ng/mL (third trimester). There was no statistical difference in the Hsp70 levels between the three trimesters. The mean Hsp70 levels were 21.9 ± 5.3 ng/mL (A), 35.3 ± 9.6 ng/mL (Ap), 9.4 ± 2.2 ng/mL (Af), 24.4 ± 3.6 ng/mL (P), 6.1 ± 0.6 ng/mL (B), and 2.4 ± 0.6 ng/mL (C). Group Ap had significantly higher Hsp70 levels than group Af (P = 0.0112) and group B (P < 0.0001). The duration of pregnancy after hospitalization for group Ap was significantly shorter than that for group Af (P = 0.0088) and group B (P < 0.0001). Group P also had significantly higher Hsp70 levels than group B (P < 0.0001). Conclusion: Because Hsp70 levels were particularly high in treatment‐resistant preterm delivery cases, Hsp70 may prove to be a useful marker for evaluating the curative effects of treatment for preterm delivery.
Bibliography:	ArticleID:JOG244 istex:C550DE2DB35BE046106F38296DD351BC34B323AD ark:/67375/WNG-B284TT9C-L ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1341-8076 1447-0756
DOI:	10.1111/j.1447-0756.2005.00244.x